Mechanisms of Resistance to PSMA Radioligand Therapy

Description

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Mechanisms of Resistance to PSMA Radioligand Therapy: Radiation Resistance Versus Dose

Mechanisms of Resistance to PSMA Radioligand Therapy

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

New York

Memorial Sloan Kettering, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Initiating treatment with Lutetium based PSMA-targeted RLT.
  • 2. Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards.
  • 3. Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for at least five days prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is approval by the interventional radiologist or the PI.
  • 4. Age \>=18 years.
  • 5. Ability to understand and the willingness to sign a written informed consent document.
  • 1. Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors).
  • 2. Patients who are not able to undergo additional study related imaging procedures.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Thomas Hope, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2024-12-31